PMID- 31802944
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung 
      Cancer: A Retrospective Study.
PG  - 9243-9251
LID - 10.2147/CMAR.S221434 [doi]
AB  - PURPOSE: Osimertinib is an oral, irreversible epidermal growth factor receptor 
      (EGFR) tyrosine kinase inhibitor (TKI) targeted for both EGFR sensitizing 
      mutations and T790M resistance mutation in patients with non-small-cell lung 
      cancer (NSCLC). We assessed efficacy and safety of osimertinib in patients with 
      pretreated NSCLC in a real-world setting. PATIENTS AND METHODS: Ninety-four 
      patients with advanced NSCLC who received osimertinib after progression of prior 
      EGFR-TKIs or chemotherapy treatments were retrospectively collected. RESULTS: In 
      patients evaluable for response analysis (n = 91), overall objective response 
      rate (ORR) was 47.3%, and disease control rate (DCR) was 90.1%. Median duration 
      of response (DoR) in responding patients was 12.5 months (95% confidence interval 
      [CI], 10.7 to 14.3). Median progression-free survival (PFS) was 8.5 months (95% 
      CI, 7.4 to 9.6) in 2nd line group, 9.1 months (95% CI, 6.6 to 11.6) in >/=3rd line 
      group, and 8.6 months (95% CI, 7.2 to 10.0) in overall population. For subgroup 
      analysis, DCR and median PFS were 91.9% and 8.6 months (95% CI, 7.2 to 10.0) in 
      patients with detectable T790M mutation, respectively, while 80.0% and 3.2 months 
      (95% CI, 0.5 to 5.9) for those without. Median PFS was significantly longer for 
      T790M-positive patients co-occurring with exon19del than with L858R (17.9 months 
      vs 7.3 months; P<0.001). Among 45 patients with metastases to the central nervous 
      system (CNS), median systemic PFS was 8.8 months (95% CI, 6.9 to 10.7), while 
      intracranial time to progression (iTTP) was not reached. Safety profile was 
      acceptable, no adverse events (AEs) related deaths was observed. CONCLUSION: 
      Osimertinib was highly active in patients with pretreated advanced NSCLC who 
      harbored EGFR T790M mutation, with manageable side-effects.
CI  - (c) 2019 Mu et al.
FAU - Mu, Yuxin
AU  - Mu Y
AD  - National Cancer Center, National Clinical Research Center for Cancer, Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, People's Republic of China.
FAU - Xing, Puyuan
AU  - Xing P
AD  - National Cancer Center, National Clinical Research Center for Cancer, Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, People's Republic of China.
FAU - Hao, Xuezhi
AU  - Hao X
AD  - National Cancer Center, National Clinical Research Center for Cancer, Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, People's Republic of China.
FAU - Wang, Yan
AU  - Wang Y
AD  - National Cancer Center, National Clinical Research Center for Cancer, Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, People's Republic of China.
FAU - Li, Junling
AU  - Li J
AD  - National Cancer Center, National Clinical Research Center for Cancer, Cancer 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 
      Beijing, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20191030
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6826191
OTO - NOTNLM
OT  - efficacy
OT  - non-small-cell lung cancer
OT  - osimertinib
OT  - safety
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/12/06 06:00
MHDA- 2019/12/06 06:01
PMCR- 2019/10/30
CRDT- 2019/12/06 06:00
PHST- 2019/07/02 00:00 [received]
PHST- 2019/10/10 00:00 [accepted]
PHST- 2019/12/06 06:00 [entrez]
PHST- 2019/12/06 06:00 [pubmed]
PHST- 2019/12/06 06:01 [medline]
PHST- 2019/10/30 00:00 [pmc-release]
AID - 221434 [pii]
AID - 10.2147/CMAR.S221434 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Oct 30;11:9243-9251. doi: 10.2147/CMAR.S221434. 
      eCollection 2019.